Key facts
- Solu Therapeutics’s last known valuation is $104.0M (Apr 2025).
- It has raised $72.0M; the latest was Early Stage VC ($41.0M) in Apr 2025.
- Notable investors include Alexandria Venture Investments, DCVC Bio, Astellas Venture Management, Biovision Ventures, Eli Lilly — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Solu Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Solu Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Solu Therapeutics
Developer of bifunctional small-molecule therapeutics designed to eliminate disease-driving cells. The company's platform combines selective small-molecule binders with proprietary antibodies and provides oncology therapeutics, eliminating cells that drive inflammatory and autoimmune diseases, enabling medical professionals to improve specificity and efficacy through deep binding pockets and reduce safety risks.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2022
- Employees
- 7
- Website
- solutherapeutics.com/
- Ownership
- Privately Held (backing)
Solu Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Solu Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Solu Therapeutics in its N-PORT filings yet. We sweep new filings monthly.